COR — The margin behind medicine distribution

Moving more medicine can lift sales while leaving a surprisingly small share of each dollar as operating profit.

On November 4, $COR reported fiscal fourth-quarter revenue of $88.4 billion, up 5.5% from a year earlier. Cencora's reported operating income was about $907 million, or 1.03% of revenue. That narrow margin makes the mix of drugs and services worth watching alongside the enormous sales total.

The company said U.S. healthcare revenue grew partly through higher sales of specialty products and GLP-1 medicines. Its adjusted gross profit margin also reflected the OneOncology acquisition, partly offset by increased sales of GLP-1 products, which carry lower gross margins. Earlier in fiscal 2026, U.S. healthcare revenue had grown 2.9% in the second quarter; the fourth quarter's growth rate was 5.4%, both measured against the respective prior-year quarters.

For fiscal 2027, Cencora forecasts adjusted earnings of $19.40–$19.75 per share. That forecast is not a reported result. Its new segment reporting will provide a useful test: compare future segment operating income and margins, not just total drug revenue, to see where growth actually becomes profit.